Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer [Thoracic Oncology]

Conclusion
Our results indicate the better efficacy of crizotinib in patients with ALK variant 1 versus non–variant 1. The ALK variant status might affect the efficacy of ALK-TKIs.

Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Yoshida, Oya, Tanaka, Shimizu, Horio, Kuroda, Sakao, Hida, Yatabe Tags: Chemotherapy Thoracic Oncology Source Type: research